Blood and immune system conditions
Explore our latest news, features and CME resources on this topic, relevant to general practice.
NICE recommends treatment for lupus
Belimumab is the only medicine specifically licensed for treating systemic lupus erythematosus.
NICE recommends treatment for hereditary angioedema
New NICE draft guidance means that close to one third of patients with hereditary angioedema in England will be eligible for berotralstat, the first oral treatment for this condition to be made available on the NHS.
Fostamatinib not recommended for refractory chronic immune thrombocytopenia
The cost-effectiveness estimates for fostamatinib compared with rituximab are higher than what NICE normally considers cost effective.
NICE recommends first treatment for rare blood disorder
Midostaurin is reocmmended as a treatment for advanced systemic mastocytosis in adults. It the first targeted therapy for this condition to be available on the NHS.
SMC accepts treatment for primary chronic immune thrombocytopenia
Avatrombopag is accepted for restricted use within NHS Scotland.
NICE publishes new rapid guideline to diagnose and treat rare blood clotting condition associated with COVID-19 vaccination
NICE has today published a new rapid COVID-19 guideline to help healthcare staff identify and treat patients who develop the rare syndrome vaccine-induced immune thrombocytopenia and thrombosis (VITT) after receiving COVID-19 vaccinations.
Belimumab not recommended for lupus in draft guidance
Belimumab had previously been available on the NHS through a managed access agreement with NICE.
